Topics:
1) Future of MS R&D
2) Will neuroimmunology be relevant to understand and treat neurodegeneration
3) Peripheral neuroimmunology – MG, CIDP, Myositis
4) why ME/CFS, Long covid are not a neuroimmunological diseases
5) how can academia help to develop therapeutic strategies
Participants
Merck | Dominic Jack & Hashem Salloukh
Novartis | Bernd Kieseier
Roche Global | Bjoern Tackenberg